Anagrelide for the treatment of thrombocythaemia in daily clinical practice: A post-marketing observational survey on efficacy and safety performed in Germany

Onkologie

Volumn 33, Issue 1-2, 2010, Pages 39-44

  Schmitz, Stephan ^a   Stauch, Martina ^b   Schlag, Rudolf ^a  

^a Gemeinschaftspraxis für Hämatologie und Onkologie ^*  (Germany)

^b Onkologische Schwerpunktpraxis   (Germany)

Author keywords

Anagrelide; Chronic myeloproliferative disease; Essential thrombocythaemia; Post marketing observational survey

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; ANTICOAGULANT AGENT; HYDROXYUREA;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLEEDING; CLINICAL PRACTICE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FEMALE; GERMANY; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MALLORY WEISS SYNDROME; NAUSEA; PNEUMONIA; POSTMARKETING SURVEILLANCE; TACHYCARDIA; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PRODUCT SURVEILLANCE, POSTMARKETING; QUINAZOLINES; THROMBOCYTHEMIA, ESSENTIAL; THROMBOSIS; YOUNG ADULT;

EID: 77249118383     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000264611     Document Type: Article

References (30)

1. Randi ML, Ruzzon E, Tezza F, Luzzatto G, Fabris F: Toxicity and side effects of hydroxyurea used for primary thrombocythemia. Platelets 2005;16: 181-184.
2. Guillot B, Bessis D, Dereure O: Mucocutaneous side effects of antineoplastic chemotherapy. Expert Opin Drug Saf 2004;3:579-587.
3. Tarumoto T, Imagawa S, Hotta T, Ohmine K, Nagai T, Takatoku M, Komatsu N, Hatake K, Ozawa K: A case of bilateral heel ulcers associated with hydroxyurea therapy for chronic myelogenous leukemia. Jpn J Clin Oncol 2000;30:159-162.
4. Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P: Long-term incidence of haematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 2006;32:417-421.
5. Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, Mazzucconi MG, Rodeghiero F, Tura S: Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004;89:215-232.
6. Shire Deutschland GmbH: Fachinformation Xagrid ® (Anagrelid). Date of information: January 2008, Fachinfoservice www.fachinfo.de [accessed February 2009].
7. Hong Y, Wang G, Del Arroyo AG, Hernandez J, Skene C, Erusalimsky JD: Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage. Leukemia 2006;20:1117-1122.
8. Thiele J, Kvasnicka HM, Fuchs N, Brunnbauer K, Volkwein N, Schmitt-Graeff A: Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. An immunohistochemical and morphometric study of sequential trephine biopsies. Haematologica 2003;88:1130-1138.
9. Birgegård G: Long-term management of thrombocytosis in essential thrombocythaemia. Ann Hematol 2009;88:1-10.
10. Birgegard G, Björkholm M, Kutti J, Lärfars G, Löfvenberg E, Markevärn B, Merup M, Palmblad J, Mauritzson N, Westin J, Samuelsson J: Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica 2004;89: 520-527.
11. Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A, Anagrelide Study Group: Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leuk Res 2005;29:481-491.
12. Steurer M, Gastl G, Jedrzejczak WW, Pytlik R, Lin W, Schlögl E, Gisslinger H: Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 2004;101:2239-2246.
13. Penninga E, Jensen BA, Hansen PB, Clausen NT, Mourits-Andersen T, Nielsen OJ, Hasselbalch HC: Anagrelide treatment in 52 patients with chronic myeloproliferative diseases. Clin Lab Haematol 2004;26:335-340.
14. Storen EC, Tefferi A: Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001;97:863-866.
15. Laguna MS, Kornblihtt LI, Marta RF, Michiels JJ, Molinas FC: Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia. Clin Appl Thromb Hemost 2000;6:157-161.
16. Mills AK, Taylor KM, Wright SJ, Bunce I, Eliadis P, Brigden MC, Seeley G, Bashford J, Olsen T, Rentoul A, Kelly C: Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia. Aust N Z J Med 1999;29:29-35.
17. Petrides PE, Beykirch MK, Trapp OM: Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany. Eur J Haematol 1998;61:71-76.
18. Anagrelide Study Group: Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 1992;92:69-76.
19. Petitt RM, Silverstein MN, Petrone ME: Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 1997;34:51-54.
20. SAS Institute: Statistical Analysis System Version 9.1. Released 2003, www.sas.com.
21. Griesshammer M, Grünewald M, Michiels JJ: Acquired thrombophilia in pregnancy: essential thrombocythemia. Semin Thromb Hemost 2003;29: 205-212.
22. Barosi G, Besses C, Birgegard G, Briere J, Cervantes F, Finazzi G, Gisslinger H, Griesshammer M, Gugliotta L, Harrison C, Hasselbalch H, Lengfelder E, Reilly JT, Michiels JJ, Barbui T: A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia 2007;21:277-280.
23. Griesshammer M, Thiele J: [A new kind of treatment for thrombocythemia: Anagrelide]. Onkologe 2006;12:1263-1274.
24. Griesshammer M: Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia. Semin Thromb Hemost 2006;32:372-380.
25. Budde U, Schaefer G, Mueller N, Egli H, Dent J, Ruggeri Z, Zimmerman T: Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 1984;64:981-985.
26. Budde U, Scharf RE, Franke P, Hartmann-Budde K, Dent J, Ruggeri ZM: Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 1993;82:1749-1757.
27. Elliott MA, Tefferi A: Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005;128:275-290.
28. Fruchtman SM, Petitt RM, Gilbert HS: Anagrelide therapy significantly reduces disease related symptoms in patients with myeloproliferative disorders. Blood 2003;102:32A-33A.
29. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T: Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-1136.
30. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR: United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353:33-45.